Tiziana Life Sciences Ltd (TLSA) Stock Price & Analysis
Tiziana Life Sciences Ltd (TLSA) closed at USD 1.05 on Thursday, October 15, 2026, up 0.00% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 1.05; the Oct 15, 2026 session ranged USD 1.02–1.07 on volume of 264,331 shares. Market capitalization is $133.62M, with a 52-week range of USD 0.76–2.15 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:19 UTC.
Also available as compact Markdown for AI agents: nexqual.com/TLSA.md
Key facts (TLSA)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (2 analysts), mean target USD 8.04 (range 7.04–9.04).
- Total return with dividends: 1Y -48.0% vs S&P 500 +18.1%; 5Y -30.5% vs S&P 500 +85.1%.
Analysts (TLSA)
Consensus Buy (mean 2.00 on a 1–5 scale), 2 analysts; mean target USD 8.04 (low 7.04, high 9.04).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-22 | BTIG | Reiterated | Buy | $7 |
| 2026-09-03 | BTIG | Initiated | Buy | $7 |
Total return (dividends reinvested) (TLSA)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -48.0% | -30.5% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -48.1% | -7.0% |
| Volatility (annualized) | 79.5% | 86.5% |
| Max drawdown | -61.9% (Oct 2025→Sep 2026) | -71.8% (Oct 2021→Apr 2024) |
Key Statistics (as of October 16, 2026 at 05:19 UTC)
| Price | USD 1.05 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 1.05 |
| Open | USD 1.05 |
| Day Range | USD 1.02 – 1.07 |
| 52-Week Range | USD 0.76 – 2.15 |
| Volume | 264,331 shares |
| Market Cap | $133.62M |
| Exchange | NCM |
Technical Analysis (TLSA)
Nexqual's technical model rates TLSA "NEUTRAL" based on 3 bullish and 2 bearish signals across 127 daily candles, as of October 16, 2026 at 05:19 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 49.49 (neutral) |
| vs SMA50 | Above (USD 1.03) |
| MACD | 0.02 (positive) |
Analyst Ratings (TLSA)
Wall Street analysts rate TLSA "Buy" based on 2 analysts, with a mean price target of USD 8.04 (range USD 7.04–9.04), per Nexqual as of October 16, 2026 at 05:19 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 8.04 |
| High Target | USD 9.04 |
| Low Target | USD 7.04 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (TLSA)
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financials & Fundamentals (TLSA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -924.32% |
| Debt / Equity | 8.77 |
| Current Ratio | 0.76 |
| Total Cash | $4.01M |
| Total Debt | $456,000 |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financial Health Score (TLSA)
Nexqual rates Tiziana Life Sciences Ltd's overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:19 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Critical — $4M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$13M (TTM) |
| Efficiency | Critical — ROE -924%, ROA -116.0% |
Ownership (TLSA)
| Insider Ownership | +47.65% |
|---|---|
| Institutional Ownership | +1.91% |
| Shares Outstanding | 127.26M |
| Float | 60.91M |
| Short % of Float | +7.26% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Leadership (TLSA)
Tiziana Life Sciences Ltd is led by Ivor R. Elrifi, CEO & Executive Director, per Nexqual as of October 16, 2026 at 05:19 UTC.
| CEO & Executive Director | Ivor R. Elrifi |
|---|---|
| Founder & Executive Chairman | Gabriele Marco Antonio Cerrone (age 53) |
| COO & CFO | Keeren Shah (age 49) |
Major Backers & Investors (TLSA)
Notable institutional backers of Tiziana Life Sciences Ltd include Dauntless Investment Group, LLC , Mid-american Wealth Advisory Group, Inc., Goldman Sachs, according to Nexqual as of October 16, 2026 at 05:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Dauntless Investment Group, LLC | 0.96% |
| Mid-american Wealth Advisory Group, Inc. | 0.27% |
| Goldman Sachs | 0.17% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:19 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt